➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
McKesson
Harvard Business School
Colorcon
AstraZeneca

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEXAMETHASONE INTENSOL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Dexamethasone Intensol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04094961 Ixazomib + Pomalidomide + Dexamethasone In MM Not yet recruiting Takeda Phase 1/Phase 2 2019-09-01 This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.
NCT04094961 Ixazomib + Pomalidomide + Dexamethasone In MM Not yet recruiting Paul G. Richardson, MD Phase 1/Phase 2 2019-09-01 This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.
NCT04216524 Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Not yet recruiting National Cancer Institute (NCI) Phase 2 2020-04-30 This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant protein consisting of IL-3 linked to a toxic agent called DT. IL-3 attaches to IL-3 receptors on tumor cells in a targeted way and delivers DT to kill them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and SL-401 with chemotherapy may be an effective treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dexamethasone Intensol

Condition Name

Condition Name for Dexamethasone Intensol
Intervention Trials
Recurrent Plasma Cell Myeloma 2
Refractory Plasma Cell Myeloma 2
Down Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dexamethasone Intensol
Intervention Trials
Multiple Myeloma 4
Neoplasms, Plasma Cell 4
Leukemia, Lymphoid 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dexamethasone Intensol

Trials by Country

Trials by Country for Dexamethasone Intensol
Location Trials
United States 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dexamethasone Intensol
Location Trials
California 2
Georgia 1
Texas 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dexamethasone Intensol

Clinical Trial Phase

Clinical Trial Phase for Dexamethasone Intensol
Clinical Trial Phase Trials
Phase 3 1
Phase 2 6
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dexamethasone Intensol
Clinical Trial Phase Trials
Not yet recruiting 7
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dexamethasone Intensol

Sponsor Name

Sponsor Name for Dexamethasone Intensol
Sponsor Trials
National Cancer Institute (NCI) 6
Janssen Pharmaceuticals 1
Takeda 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dexamethasone Intensol
Sponsor Trials
NIH 6
Other 6
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Moodys
McKinsey
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.